title: Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.
abstract: Eighty-four consecutive subjects with nonalcoholic fatty liver disease (NAFLD) were tested for non-organ-specific autoantibodies (NOSA) by indirect immunoflorescence. Indices of insulin resistance and biochemical and anthropometric parameters were assessed. The overall prevalence of anti-nuclear-antibodies (ANA), smooth muscle antibodies (SMA) and anti-mitochondrial-antibodies (AMA) was 35.7% (30/84), 18 subjects (21.4%) being positive for ANA, 4 (4.7%) for SMA, 6 for ANA and SMA, and 2 for AMA. NOSA-positive subjects were older (P < 0.01) and mostly females (63.3%). No significant difference was found in the age-corrected parameters studied, except for copper and ceruloplasmin, which was more elevated in NOSA-positive patients. The subset of high titer (>1:100) ANA-positive patients had significantly (P < 0.05) greater insulin resistance than ANA-negative patients. In contrast, SMA-positive patients had higher gammaglobulin and significantly lower insulin resistance as compared to high-titer ANA-positive patients. In 3 NOSA-positive but not in NOSA-negative patients, liver biopsy disclosed features of overlapping NASH with autoimmune hepatitis, partially responding to diet combined with steroid treatment. In conclusion, NOSA positivity in NAFLD is more prevalent than in the general population. High-titre ANA but not SMA positivity is associated with insulin resistance.
authors.affiliation: Dipartimento di Medicina Interna-Medicina III, Università degli Studi di Modena e Reggio Emilia, Policlinico, Via del Pozzo 71, 41100 Modena, MO, Italy. loria.paola@unimore.it
authors.forename: Paola
authors.initials: P
authors.lastname: Loria
authors.forename: Amedeo
authors.initials: A
authors.lastname: Lonardo
authors.forename: Francesca
authors.initials: F
authors.lastname: Leonardi
authors.forename: Cristina
authors.initials: C
authors.lastname: Fontana
authors.forename: Lucia
authors.initials: L
authors.lastname: Carulli
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Verrone
authors.forename: Andrea
authors.initials: A
authors.lastname: Borsatti
authors.forename: Marco
authors.initials: M
authors.lastname: Bertolotti
authors.forename: Fabio
authors.initials: F
authors.lastname: Cassani
authors.forename: Alberto
authors.initials: A
authors.lastname: Bagni
authors.forename: Paolo
authors.initials: P
authors.lastname: Muratori
authors.forename: Dorval
authors.initials: D
authors.lastname: Ganazzi
authors.forename: Francesco B
authors.initials: FB
authors.lastname: Bianchi
authors.forename: Nicola
authors.initials: N
authors.lastname: Carulli
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D005234:Fatty Liver / Q000097:blood / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D008875:Middle Aged; D008930:Mitochondria, Liver / Q000276:immunology; D009130:Muscle, Smooth / Q000276:immunology; D016036:Seroepidemiologic Studies
chemical_list: D001323:Autoantibodies